Skip to main content
Premium Trial:

Request an Annual Quote

Acadia Raises $10.7M From European Investors

Premium

SAN DIEGO, Calif.--Acadia Pharmaceuticals, a privately held genomics drug discovery company headquartered here, with chemical research facilities in Copenhagen, raised nearly $10.7 million through a private placement of stock in late August. ABN AMRO Ventures, Amsterdam, led the financing, which also included participation from leading Swedish institutional investors. Danish institutional investors included previous Acadia investors Dansk Kapitalanlaeg, Municipal Employees Life Insurance, and LD Pensions.

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.